The Role of Metabolic Reprogramming in Liver Cancer and Its Clinical Perspectives

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Nov 29

PMID 39610917

Authors

Mengxiao Lu

Yingjie Wu

MinMing Xia

Yixin Zhang

Affiliations

Soon will be listed here.

Abstract

Primary liver cancer (PLC), which includes hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), remains a leading cause of cancer-related death worldwide. Chronic liver diseases, such as hepatitis B and C infections and metabolic dysfunction-associated steatotic liver disease (MASLD), are key risk factors for PLC. Metabolic reprogramming, a defining feature of cancer, enables liver cancer cells to adapt to the demands of rapid proliferation and the challenging tumor microenvironment (TME). This manuscript examines the pivotal role of metabolic reprogramming in PLC, with an emphasis on the alterations in glucose, lipid, and amino acid metabolism that drive tumor progression. The Warburg effect, marked by increased glycolysis, facilitates rapid energy production and biosynthesis of cellular components in HCC. Changes in lipid metabolism, including elevated fatty acid synthesis and lipid oxidation, support membrane formation and energy storage essential for cancer cell survival. Amino acid metabolism, particularly glutamine utilization, supplies critical carbon and nitrogen for nucleotide synthesis and maintains redox homeostasis. These metabolic adaptations not only enhance tumor growth and invasion but also reshape the TME, promoting immune escape. Targeting these metabolic pathways presents promising therapeutic opportunities for PLC. This review underscores the interaction between metabolic reprogramming and tumor immunity, suggesting potential metabolic targets for innovative therapeutic strategies. A comprehensive understanding of PLC's intricate metabolic landscape may lead to more effective treatments and better patient outcomes. Integrating metabolomics, genomics, and proteomics in future research will be vital for identifying precise therapeutic targets and advancing personalized therapies for liver cancer.

References

Csibi A, Fendt S, Li C, Poulogiannis G, Choo A, Chapski D . The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell. 2021; 184(8):2256. DOI: 10.1016/j.cell.2021.03.059. View

Kim G, Lee H, Choe J, Kim M, Lee M, Chang H . Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol. 2017; . DOI: 10.1016/j.jhep.2017.09.012. View

Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N . The cancer metabolic reprogramming and immune response. Mol Cancer. 2021; 20(1):28. PMC: 7863491. DOI: 10.1186/s12943-021-01316-8. View

Potter M, Newport E, Morten K . The Warburg effect: 80 years on. Biochem Soc Trans. 2016; 44(5):1499-1505. PMC: 5095922. DOI: 10.1042/BST20160094. View

Missiaen R, Anderson N, Kim L, Nance B, Burrows M, Skuli N . GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment. Cell Metab. 2022; 34(8):1151-1167.e7. PMC: 9357184. DOI: 10.1016/j.cmet.2022.06.010. View

Pan L, Feng F, Wu J, Fan S, Han J, Wang S . Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells. Pharmacol Res. 2022; 181:106270. DOI: 10.1016/j.phrs.2022.106270. View

Faloppi L, Del Prete M, Casadei Gardini A, Santini D, Silvestris N, Bianconi M . The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. Sci Rep. 2016; 6:24136. PMC: 4827080. DOI: 10.1038/srep24136. View

Molenaar R, Coelen R, Khurshed M, Roos E, Caan M, van Linde M . Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with -mutated or -mutated solid tumours. BMJ Open. 2017; 7(6):e014961. PMC: 5541450. DOI: 10.1136/bmjopen-2016-014961. View

Lu M, Lu L, Dong Q, Yu G, Chen J, Qin L . Elevated G6PD expression contributes to migration and invasion of hepatocellular carcinoma cells by inducing epithelial-mesenchymal transition. Acta Biochim Biophys Sin (Shanghai). 2018; 50(4):370-380. DOI: 10.1093/abbs/gmy009. View

10.

Singhal A, Li B, OReilly E . Targeting KRAS in cancer. Nat Med. 2024; 30(4):969-983. PMC: 11845254. DOI: 10.1038/s41591-024-02903-0. View

11.

Kruiswijk F, Labuschagne C, Vousden K . p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol. 2015; 16(7):393-405. DOI: 10.1038/nrm4007. View

12.

De Santis M, Bockorny B, Hirsch E, Cappello P, Martini M . Exploiting pancreatic cancer metabolism: challenges and opportunities. Trends Mol Med. 2024; 30(6):592-604. DOI: 10.1016/j.molmed.2024.03.008. View

13.

Rocha N, Barbisan L, de Oliveira M, de Camargo J . Effects of fasting and intermittent fasting on rat hepatocarcinogenesis induced by diethylnitrosamine. Teratog Carcinog Mutagen. 2002; 22(2):129-38. DOI: 10.1002/tcm.10005. View

14.

Gupta A, Das A, Majumder K, Arora N, Mayo H, Singh P . Obesity is Independently Associated With Increased Risk of Hepatocellular Cancer-related Mortality: A Systematic Review and Meta-Analysis. Am J Clin Oncol. 2017; 41(9):874-881. PMC: 5700876. DOI: 10.1097/COC.0000000000000388. View

15.

DeWaal D, Nogueira V, Terry A, Patra K, Jeon S, Guzman G . Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. Nat Commun. 2018; 9(1):446. PMC: 5792493. DOI: 10.1038/s41467-017-02733-4. View

16.

Ferretti A, Hidalgo F, Tonucci F, Almada E, Pariani A, Larocca M . Metformin and glucose starvation decrease the migratory ability of hepatocellular carcinoma cells: targeting AMPK activation to control migration. Sci Rep. 2019; 9(1):2815. PMC: 6391381. DOI: 10.1038/s41598-019-39556-w. View

17.

Song N, Yun U, Yang S, Wu C, Seo C, Gwon A . Notch1 deficiency decreases hepatic lipid accumulation by induction of fatty acid oxidation. Sci Rep. 2016; 6:19377. PMC: 4726366. DOI: 10.1038/srep19377. View

18.

Allen A, Hicks S, Mara K, Larson J, Therneau T . The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study. J Hepatol. 2019; 71(6):1229-1236. PMC: 6921701. DOI: 10.1016/j.jhep.2019.08.018. View

19.

Tomizawa M, Shinozaki F, Motoyoshi Y, Sugiyama T, Yamamoto S, Ishige N . 2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells. Oncol Lett. 2017; 13(2):800-804. PMC: 5351389. DOI: 10.3892/ol.2016.5510. View

20.

Mittal B . Subcutaneous adipose tissue & visceral adipose tissue. Indian J Med Res. 2019; 149(5):571-573. PMC: 6702693. DOI: 10.4103/ijmr.IJMR_1910_18. View